IP Verse

Human Anti-Alpha-Synuclein Antibodies - EP2949666

The patent EP2949666 was granted to Biogen Neuroscience on Dec 19, 2018. The application was originally filed on Dec 21, 2009 under application number EP15166032A. The patent is currently recorded with a legal status of "Revoked".

EP2949666

BIOGEN NEUROSCIENCE
Application Number
EP15166032A
Filing Date
Dec 21, 2009
Status
Revoked
Feb 2, 2024
Publication Date
Dec 19, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MERCK SHARP & DOHMESep 19, 2019HORGANADMISSIBLE
GLEISS GROSSE SCHRELL UND PARTNER MBBSep 18, 2019SCHRELLADMISSIBLE
BREUERSep 17, 2019BREUERADMISSIBLE

Patent Citations (50) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0239400
DESCRIPTIONEP0396387
DESCRIPTIONUS2002123057
DESCRIPTIONUS2003157641
DESCRIPTIONUS4741900
DESCRIPTIONUS5116964
DESCRIPTIONUS5122464
DESCRIPTIONUS5225538
DESCRIPTIONUS5314995
DESCRIPTIONUS5658570
DESCRIPTIONUS5736137
DESCRIPTIONUS5837821
DESCRIPTIONUS5892019
DESCRIPTIONUS5939598
DESCRIPTIONUS6159730
DESCRIPTIONUS6193980
DESCRIPTIONUS6413777
DESCRIPTIONWO0030680
DESCRIPTIONWO0034317
DESCRIPTIONWO02060955
DESCRIPTIONWO02096948
DESCRIPTIONWO2005018572
DESCRIPTIONWO2005047860
DESCRIPTIONWO2007011907
DESCRIPTIONWO2007021255
DESCRIPTIONWO2008081008
DESCRIPTIONWO2008103472
DESCRIPTIONWO8605807
DESCRIPTIONWO8809344
DESCRIPTIONWO8901036
DESCRIPTIONWO8909622
DESCRIPTIONWO8912624
DESCRIPTIONWO9007861
DESCRIPTIONWO9110741
DESCRIPTIONWO9114438
DESCRIPTIONWO9208495
DESCRIPTIONWO9402602
DESCRIPTIONWO9409817
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9852976
DESCRIPTIONWO9950300
OPPOSITIONUS2008014194
OPPOSITIONWO2004041067
OPPOSITIONWO2005047860
OPPOSITIONWO2007011907
OPPOSITIONWO2009133521
OPPOSITIONWO2010069603
OTHERWO2004041067
OTHERWO2007012061

Non-Patent Literature (NPL) Citations (152) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ADV. IN DRUG DELIV. REV., (2002), vol. 54, page 531
DESCRIPTION- "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", BALDWIN ET AL., Monoclonal Antibodies For Cancer Detection And Therapy, ACADEMIC PRESS, (1985), pages 303 - 16
DESCRIPTION- ARNON ET AL., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", ARNON ET AL., REISFELD ET AL., Monoclonal Antibodies And Cancer Therapy, ALAN R. LISS, INC., (1985), pages 243 - 56
DESCRIPTION- ARUFFO ET AL., CELL, (1990), vol. 61, pages 1303 - 1313
DESCRIPTION- ASHKENAZI ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 10535 - 10539
DESCRIPTION- BABA ET AL., AM. J. PATHOL., (1998), vol. 152, pages 879 - 884
DESCRIPTION- B. C. JOHNSON, Posttranslational Covalent Modification Of Proteins, ACADEMIC PRESS, (1983), pages 1 - 12
DESCRIPTION- BEBBINGTON; HENTSCHEL, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, ACADEMIC PRESS, (1987), vol. 3
DESCRIPTION- BERKS, TIBTECH, (1994), vol. 12, pages 352 - 364
DESCRIPTION- BUTLER, METH. ENZYMOL., (1981), vol. 73, pages 482 - 523
DESCRIPTION- BYERS, SEMINARS CELL. BIOL., (1991), vol. 2, pages 59 - 70
DESCRIPTION- BYRN ET AL., NATURE, (1990), vol. 344, pages 667 - 670
DESCRIPTION- CAPON ET AL., NATURE, (1989), vol. 337, pages 525 - 531
DESCRIPTION- CHEUNG ET AL., VIROLOGY, (1990), vol. 176, pages 546 - 552
DESCRIPTION- CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
DESCRIPTION- COCKETT ET AL., BIO/TECHNOLOGY, (1990), vol. 8, page 2
DESCRIPTION- COLBERRE-GARAPIN ET AL., J. MOL. BIOL., (1981), vol. 150, page 1
DESCRIPTION- CROUSE ET AL., MOL. CELL. BIOL., (1983), vol. 3, page 257
DESCRIPTION- DE HAARD ET AL., J. BIOL. CHEM., (1999), vol. 26, pages 18218 - 18230
DESCRIPTION- DOENECKE ET AL., LEUKEMIA, (1997), vol. 11, pages 1787 - 1792
DESCRIPTION- EL-AGNAF ET AL., FASEB J., (2006), vol. 20, pages 419 - 425
DESCRIPTION- EMADI ET AL., J. MOL. BIOL., (2007), vol. 368, pages 1132 - 1144
DESCRIPTION- EXPERT OPIN. BIOL. THER., (2005), pages 237 - 241
DESCRIPTION- FANGER, IMMUNOL. TODAY, (1991), vol. 12, pages 51 - 54
DESCRIPTION- FOECKING ET AL., GENE, (1986), vol. 45, page 101
DESCRIPTION- GASCOIGNE ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 2936 - 2940
DESCRIPTION- GENTZ ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 821 - 824
DESCRIPTION- GEORGE ET AL., EXP. NEUROL., (2008), vol. 210, pages 788 - 92
DESCRIPTION- GEORGE, GENOME BIOL., (20011220), vol. 3
DESCRIPTION- GIASSON ET AL., J. NEUROSCI. RES., (2000), vol. 59, pages 528 - 33
DESCRIPTION- GIASSON ET AL., NEURON, (2002), vol. 34, pages 521 - 533
DESCRIPTION- GILLILAND ET AL., TISSUE ANTIGENS, (1996), vol. 47, pages 1 - 20
DESCRIPTION- GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
DESCRIPTION- GOLDSPIEL ET AL., CLINICAL PHARMACY, (1993), vol. 12, pages 488 - 505
DESCRIPTION- HAMMERLING ET AL., Monoclonal Antibodies and T-Cell Hybridomas, ELSEVIER, (1981), pages 563 - 681
DESCRIPTION- HARLOW ET AL., Antibodies: A Laboratory Manual, 2nd ed., COLD SPRING HARBOR LABORATORY PRESS, (1988), pages 27 - 28
DESCRIPTION- HELLSTROM ET AL., "Antibodies For Drug Delivery", HELLSTROM ET AL., ROBINSON ET AL., Controlled Drug Delivery, 2nd ed., MARCEL DEKKER, INC., (1987), pages 623 - 53
DESCRIPTION- INOUYE; INOUYE, NUCLEIC ACIDS RES., (1985), vol. 13, pages 3101 - 3109
DESCRIPTION- IWAI ET AL., BIOCHEMISTRY, (1995), vol. 34, pages 10139 - 10145
DESCRIPTION- JAKES ET AL., NEUROSCIENCE LETTERS, (1999), vol. 269, pages 13 - 16
DESCRIPTION- JENSEN ET AL., BIOCHEM. J., (1995), vol. 310, pages 91 - 94
DESCRIPTION- JONES, GENETICS, (1977), vol. 85, page 12
DESCRIPTION- KAHLE ET AL., J. NEUROSCI., (2000), vol. 20, pages 6365 - 73
DESCRIPTION- KINGSMAN ET AL., GENE, (1979), vol. 7, page 141
DESCRIPTION- KIRKLAND ET AL., J. IMMUNOL., (1986), vol. 137, pages 3614 - 3619
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, page 495
DESCRIPTION- KOHLER, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 2197
DESCRIPTION- KUSNEZOW ET AL., MOL. CELL PROTEOMICS, (2006), vol. 5, pages 1681 - 1696
DESCRIPTION- KUTMEIER ET AL., BIOTECHNIQUES, (1994), vol. 17, page 242
DESCRIPTION- LEONG ET AL., CYTOKINE, (2001), vol. 16, page 106
DESCRIPTION- LEONG ET AL., CYTOKINE, (2001), vol. 16, pages 106 - 119
DESCRIPTION- LESSLAUER ET AL., EUR. J. IMMUNOL., (1991), vol. 27, pages 2883 - 2886
DESCRIPTION- LINSLEY ET AL., J. EXP. MED., (1991), vol. 173, pages 721 - 730
DESCRIPTION- LISLEY ET AL., J. EXP. MED., (1991), vol. 174, pages 561 - 569
DESCRIPTION- LOWY ET AL., CELL, (1980), vol. 22, page 817
DESCRIPTION- MALMBORG, J. IMMUNOL. METHODS, (1995), vol. 183, pages 7 - 13
DESCRIPTION- MARKS ET AL., MOL. BIOL., (1991), vol. 222, pages 581 - 597
DESCRIPTION- MASLIAH ET AL., NEURON, (2005), vol. 46, pages 857 - 868
DESCRIPTION- MILLER; MESSER, MOLECULAR THERAPY, (2005), vol. 12, pages 394 - 401
DESCRIPTION- MOLDENHAUER ET AL., SCAND. J. IMMUNOL., (1990), vol. 32, pages 77 - 82
DESCRIPTION- MOREL ET AL., MOLEC. IMMUNOL., (1988), vol. 25, pages 7 - 15
DESCRIPTION- MORGAN; ANDERSON, ANN. REV. BIOCHEM., (1993), vol. 62, pages 191 - 217
DESCRIPTION- MULLER ET AL., EXPERT OPIN. BIOL. THER., (2005), pages 237 - 241
DESCRIPTION- MULLIGAN; BERG, PROC. NATL. ACAD. SCI. USA, (1981), vol. 78, page 2072
DESCRIPTION- MULLIGAN, SCIENCE, (1993), vol. 260, pages 926 - 932
DESCRIPTION- NEFF ET AL., AUTOIMMUN. REV., (2008), vol. 7, pages 501 - 507
DESCRIPTION- O'HARE ET AL., PROC. NATL. ACAD. SCI. USA, (1981), vol. 78, page 1527
DESCRIPTION- PAPACHRONI ET AL., J. NEUROCHEM., (2007), vol. 101, pages 749 - 756
DESCRIPTION- PEPPEL ET AL., J. EXP. MED., (1991), vol. 174, pages 1483 - 1489
DESCRIPTION- PROUDFOOT, NATURE, (1986), vol. 322, page 52
DESCRIPTION- RATTAN ET AL., ANN. NY ACAD. SCI., (1992), vol. 663, pages 48 - 62
DESCRIPTION- REMINGTON, The Science and Practice of Pharmacy, UNIVERSITY OF SCIENCES IN PHILADELPHIA, (2000), ISBN 0-683-306472
DESCRIPTION- RIDGWAY; GORMAN, J. CELL. BIOL., (1991), vol. 115
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
DESCRIPTION- ROBERT ET AL., PROTEIN ENG. DES. SEL., (20081016), pages 1741 - 0134
DESCRIPTION- ROUX ET AL., J. IMMUNOL., (1998), vol. 161, page 4083
DESCRIPTION- RUTHER ET AL., EMBO J., (1983), vol. 2, page 1791
DESCRIPTION- SANTERRE ET AL., GENE, (1984), vol. 30, page 147
DESCRIPTION- SCHIER, HUMAN ANTIBODIES HYBRIDOMAS, (1996), vol. 7, pages 97 - 105
DESCRIPTION- SEIFTER ET AL., METH. ENZYMOL., (1990), vol. 182, pages 626 - 646
DESCRIPTION- SEITZ ET AL., KONGRESS DER DEUTSCHEN GESELLSCHAFT FUR NEUROLOGIE MIT FORTBILDUNGSAKADEMIE HAMBURG, (20080910), vol. 81
DESCRIPTION- SMITH; WATERMAN, ADVANCES IN APPLIED MATHEMATICS, (1981), vol. 2, pages 482 - 489
DESCRIPTION- STAHLI ET AL., METHODS IN ENZYMOLOGY, (1983), vol. 9, pages 242 - 253
DESCRIPTION- STAMENKOVIC ET AL., CELL, (1991), vol. 66, pages 1133 - 1144
DESCRIPTION- STINCHCOMB ET AL., NATURE, (1979), vol. 282, page 39
DESCRIPTION- SZYBALSKA; SZYBALSKI, PROC. NATL. ACAD. SCI. USA, (1992), vol. 48, page 202
DESCRIPTION- THORPE ET AL., "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE ET AL., PINCHERA ET AL., Monoclonal Antibodies '84: Biological And Clinical Applications, (1985), pages 475 - 506
DESCRIPTION- TIB TECH, (1993), vol. 11, pages 155 - 215
DESCRIPTION- TOLSTOSHEV, ANN. REV. PHARMACOL. TOXICOL., (1993), vol. 32, pages 573 - 596
DESCRIPTION- TRAUNECKER ET AL., NATURE, (1989), vol. 339, pages 68 - 70
DESCRIPTION- TSCHEMPER ET AL., GENE, (1980), vol. 10, page 157
DESCRIPTION- UEDA ET AL., PNAS USA, (1993), vol. 90, pages 1282 - 11286
DESCRIPTION- UEDA ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1993), vol. 90, pages 1282 - 1286
DESCRIPTION- VAN DER PUTTEN ET AL., J. NEUROSCI., (2000), vol. 20, pages 6021 - 6029
DESCRIPTION- VAN HEEKE; SCHUSTER, J. BIOL. CHEM., (1989), vol. 24, pages 5503 - 5509
DESCRIPTION- VOLLER, A., "The Enzyme Linked Immunosorbent Assay (ELISA", MICROBIOLOGICAL ASSOCIATES QUARTERLY PUBLICATION, WALKERSVILLE, MD., DIAGNOSTIC HORIZONS, (1978), vol. 2, pages 1 - 7
DESCRIPTION- VOLLER ET AL., J. CLIN. PATHOL., (1978), vol. 31, pages 507 - 520
DESCRIPTION- WATSON ET AL., J. CELL. BIOL., (1990), vol. 110, pages 2221 - 2229
DESCRIPTION- WATSON ET AL., NATURE, (1991), vol. 349, pages 164 - 167
DESCRIPTION- WAXMAN ET AL., ACTA NEUROPATHOL., (2008), vol. 116, pages 37 - 46
DESCRIPTION- WEIR ET AL., BIOCHEM. SOC. TRANSACTIONS, (2002), vol. 30, page 512
DESCRIPTION- WIGLER ET AL., CELL, (1977), vol. 11, page 223
DESCRIPTION- WIGLER ET AL., NATL. ACAD. SCI. USA, (1980), vol. 77, page 357
DESCRIPTION- WILSON ET AL., CELL, (1984), vol. 37, page 767
DESCRIPTION- WOULFE ET AL., NEUROLOGY, (2002), vol. 58, pages 1435 - 1436
DESCRIPTION- WU; WU, BIOTHERAPY, (1991), vol. 3, pages 87 - 95
DESCRIPTION- ZETTMEISSL ET AL., DNA CELL BIOL. USA, (1990), vol. 9, pages 347 - 353
DESCRIPTION- THORPE ET AL., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., (1982), vol. 62, doi:doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 158, XP001179872
OPPOSITION- CHANDRA et al., "alpha-Synuclein, CSPalpha, Snares and Neuroprotection In Vivo", Molecular and Therapeutic Insights From Model Systems, (20080000), pages 295 - 296, XP055643918
OPPOSITION- C. LAVEDAN et al., "Absence of Mutation in the beta and gamma Synuclien genes in Familial Autosomal Dominant Parkinson's Disease", DNA Research, (19980000), vol. 5, no. 6, pages 401 - 402, XP055643945
OPPOSITION- E. TRAGGIAI et al., "An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus", Nature Medicine,, (20040000), vol. 10, pages 871 - 875, XP002385893
OPPOSITION- GRIFFITHS A.D. et al., "ISOLATION OF HIGH AFFINITY HUMAN ANTIBODIES DIRECTLY FROM LARGE SYNTHETIC REPERTOIRES", The EMBO Journal, (19940000), vol. 13, pages 3245 - 3260, XP000455240
OPPOSITION- KAHLE et al., "SUBCELLULAR LOCALIZATION OF WILD-TYPE AND PARKINSON'S DISEASE-ASSOCIATED MUTANT ALPHA-SYNUCLEIN IN HUMAN AND TRANSGENIC MOUSE BRAIN", J. Neurosci., (20000901), vol. 20, no. 17, pages 6365 - 6373, XP000946652
OPPOSITION- KAHLE et al., "Subcellular localization of wild-type and Parkinson's disease- associated mutant alpha-synuclein in human and transgenic mouse brain", The Journal of Neuroscience, (20000000), vol. 20, no. 17, pages 6365 - 6373, XP000946652
OPPOSITION- X. YU et al., "Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors", Nature, (20080000), vol. 455, pages 532 - 536, XP055643931
OPPOSITION- VUCHELEN A. et al., "H-1, C-13 and N-15 assignments of a camelid nanobody directed against human alpha-synuclein", Biomol NMR Assign., (20090000), vol. 3, pages 231 - 233, XP002656431
OPPOSITION- PRESTA L.G. et al., "Antibody engineering", Current Opinion in Biotechnology, (19920000), vol. 3, pages 394 - 398, XP023601588
OPPOSITION- MAGUIRE-SEISS et al., "Identification of human alpha-synuclein specific single chain antibodies", Biochemical and Biophysical Research Communications, (20060000), vol. 349, pages 1198 - 1205, XP024924560
OPPOSITION- MAGUIRE-ZEISS et al., "Identification of human alpha-synuclein specific single chain antibodies", Biochemical and Biophysical Research Communications, (20061103), vol. 349, no. 4, pages 1198 - 1205, XP005660723
OPPOSITION- MAGUIRE-ZEISS KA, "Identification of human alpha-synuclein specific single chain antibodies", BBRC, (20060000), vol. 349, pages 1198 - 1205, XP024924560
OPPOSITION- PRESTA L.G. et al., "Selection, design, and engineering of therapeutic antibodies", Journal of Allergy and Clinical Immunology, (20050000), pages 731 - 736, XP005094459
OPPOSITION- EMADI et al., "Isolation of a Human Single Chain Antibody Fragment Against Oligomeric α-Synuclein that Inhibits Aggregation and Prevents α-Synuclein-induced Toxicity", Journal of Molecular Biology, (20070417), vol. 368, no. 4, pages 1132 - 114, XP022030022
OPPOSITION- LYNCH et al., "An scFv Intrabody against the Nonamyloid Component of alpha-Synuclein Reduces Intracellular Aggregation and Toxicity", J. Mol. Biol., (20071205), vol. 377, no. 1, pages 136 - 147, XP022501449
OPPOSITION- LYNCH, S.M. et al., "An scFv Intrabody against the Nonamyloid Component of alpha-Synuclein Reduces Intracellular Aggregation and Toxicity", J. Mol., Biol., (20080300), vol. 377, pages 136 - 147, XP022501449
OPPOSITION- WEIHOFEN A. et al., "Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models", Neurobiology of Disease, (20190000), vol. 124, pages 276 - 288, XP085589927
OPPOSITION- ZHOU et al., "A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed a-synuclein", MOLECULAR THERAPY, (20041206), vol. 10, pages 1023 - 1031, XP004651493
OPPOSITION- PERRIN et al., "Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines", Neuroscience Letters, (20030000), vol. 349, pages 133 - 135, XP055068613
OPPOSITION- JAKES et al., "Epitope Mapping of LB509, a Monocional Directed Against Human alpha-Synuclein", Neuroscience Letters, (19990000), vol. 269, pages 13 - 16, XP003016505
OPPOSITION- JAKES et al., "Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein", Neuroscience Letters, (19990000), vol. 269, pages 13 - 16, XP003016505
OPPOSITION- JAKES, R. et al., "Epitope Mapping of LB509, a Monocional Directed Against Human alpha-Synuclein", Neuroscience Letters, (19990000), vol. 269, pages 13 - 16, XP003016505
OPPOSITION- EMADI S. et al., "Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments", Biochemistry 2004, (20040000), vol. 43, pages 2871 - 2878, XP002517647
OPPOSITION- LONBERG N., "Human antibodies from transgenic animals", Nature Biotechnology, (20050000), vol. 23, pages 1117 - 1125, XP002442149
OPPOSITION- EL-AGNAF, O.M.A. et al., "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease", FASEB J., (20060000), vol. 20, pages 419 - 425, XP009109458
OPPOSITION- LAVEDAN C, "The Synuclein Family", Genome Research, (19980000), vol. 8, pages 871 - 880, XP055643961
OPPOSITION- PAPACHRONI et al., "Autoantibodies to alpha-synuclein in inherited Parkinson's disease", Journal of Neurochemistry, (20070000), vol. 101, pages 749 - 756, XP002530228
OPPOSITION- VAIKATH N. N. et al., "Antibodies against alpha‐synuclein: tools and therapies", Journal of Neurochemistry, (20190000), vol. 150, pages 612 - 625, XP055643972
OPPOSITION- C.P. SIMMONS et al., "Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza", PLoS Med., (20070000), vol. 4, pages 928 - 936, XP002568898
OTHER- PHILIPP J. KAHLE; MANUELA NEUMANN; LAURENCE OZMEN; VERONIKA MUELLER; HELMUT JACOBSEN; ALICE SCHINDZIELORZ; MASAYASU OKOCHI; UWE LE, "Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant a-Synuclein in Human and Transgenic Mouse Brain", The Journal of Neuroscience, (20000901), vol. 20, no. 17, pages 6365 - 6373, XP000946652
OTHER- D.W. MILLER; S.M. HAGUE; J. CLARIMON; M. BAPTISTA; K. GWINN-HARDY; M.R. COOKSON; A.B. SINGLETON, "Alpha-Synuclein in blood and brain from familial Parkinson disease withSNCA locus triplication", Neurology, (20040525), vol. 62, no. 10, pages 1835 - 1838, XP055481875
OTHER- MAKIKO YAMASHITA; YOSHINROI KATAKURA; SANETAKA SHIRAHATA, "Recent advances in the generation of human monoclonal antibody", Cytotechnology, (20071200), vol. 55, no. 2-3, pages 55 - 60, XP019550372
OTHER- ROSS JAKES; R. ANTHONY CROWTHER; VIRGINIA M.-Y. LEE; JOHN Q. TROJANOWSKI; TAKESHI IWATSUBO; MICHEL GOEDERT, "Epitope mapping of LB509, a monoclonal antibody directed against human a-synuclein", Neuroscience Letters, (19990000), vol. 269, pages 13 - 16, XP003016505
OTHER- RONIT SHARON; IFAT BAR-JOSEPH; MATTHEW P. FROSCH; DOMINIC M. WALSH; JAMES A. HAMILTON; DENNIS J. SELKOE, "The Formation of Highly Soluble Oligomers of Alpha-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease", Neuron, (20030220), vol. 37, no. 4, pages 583 - 595, XP055481874
OTHER- MICHAEL L. KRAMER; WALTER J. SCHULZ-SCHAEFFER, "Presynaptic alpha-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies", The Journal of Neuroscience, (20070207), vol. 27, no. 6, pages 1405 - 1410, XP055481876
SEARCH- ELISA A WAXMAN ET AL, "Characterization of antibodies that selectively detect Î+--synuclein in pathological inclusions", ACTA NEUROPATHOLOGICA, SPRINGER, BERLIN, DE, (20080415), vol. 116, no. 1, ISSN 1432-0533, pages 37 - 46, XP019628809 [A] 1-15 * page 38, column L, paragraph 3 *
SEARCH- LIPPA C F ET AL, "ANTIBODIES TO ALPHA-SYNUCLEIN DETECT LEWY BODIES IN MANY DOWN'S SYNDROME BRAINS WITH ALZHEIMER'S DISEASE", ANNALS OF NEUROLOGY, JOHN WILEY AND SONS, BOSTON, US, (19990301), vol. 45, no. 3, ISSN 0364-5134, pages 353 - 357, XP008074304 [A] 1-15 * abstract *
SEARCH- GIASSON B I ET AL, "A Panel of Epitope-Specific Antibodies Detects Protein Domains Distributed Throughout Human alpha-Synuclein in Lewy Bodies of Parkinson's Disease", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, (20000201), vol. 59, ISSN 0360-4012, pages 528 - 533, XP003016506 [A] 1-15 * page 530, column L, paragraph 3 *
SEARCH- NEFF FRAUKE ET AL, "Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.", AUTOIMMUNITY REVIEWS JUN 2008, (200806), vol. 7, no. 6, ISSN 1568-9972, pages 501 - 507, XP022732412 [X] 1,2,4-8 * page 503, column L - page 504, column R * [I] 3,9-15
SEARCH- ZHANG L ET AL, "Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: An immunogold electron microscopic study using a C-terminal specific monoclonal antibody", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1244, ISSN 0006-8993, (20081209), pages 40 - 52, (20080904), XP025679551 [A] 1-15 * abstract *
SEARCH- EMADI ET AL, "Isolation of a Human Single Chain Antibody Fragment Against Oligomeric alpha-Synuclein that Inhibits Aggregation and Prevents alpha-Synuclein-induced Toxicity", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20070417), vol. 368, no. 4, ISSN 0022-2836, pages 1132 - 1144, XP022030022 [A] 1-15 * the whole document *
SEARCH- LYNCH ET AL, "An scFv Intrabody against the Nonamyloid Component of alpha-Synuclein Reduces Intracellular Aggregation and Toxicity", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20071205), vol. 377, no. 1, ISSN 0022-2836, pages 136 - 147, XP022501449 [A] 1-15 * abstract *
SEARCH- EMADI SHARAREH ET AL, "Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 43, no. 10, ISSN 0006-2960, (20040316), pages 2871 - 2878, (20040220), XP002517647 [A] 1-15 * the whole document *
SEARCH- PAPACHRONI KATERINA K ET AL, "Autoantibodies to alpha-synuclein in inherited Parkinson's disease.", JOURNAL OF NEUROCHEMISTRY MAY 2007, (200705), vol. 101, no. 3, ISSN 0022-3042, pages 749 - 756, XP002530228 [X] 1,2,4-8 * page 755, column L, paragraph 2; tables 2,3 * [I] 3,9-15

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents